An observational study in Acute Lymphoblastic Leukemia, sponsored by Versailles Hospital. Recruiting at 23 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Versailles Hospital · Observational
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
2,061 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 490 are open to participants now.
This study's planned enrollment of 100 is below the median of 120 across 300 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →Versailles Hospital is the lead sponsor of 74 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Acute Lmphoblastic Leukaemia with Philadelphia chromosome or BCR::ABL1 positive
Exclusion Criteria:
Overall survival by 12 months
Time frame: 12 months
overal survival by 36 months
Time frame: 36 months
proportion of complete remission
Time frame: 36 months
the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood
Time frame: 36 months
the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood
Time frame: 36 months
Event free survival
Time frame: 36 months
Relapse free survival
Time frame: 36 months
the incidence ofBCR..ABL1 TK mutations
Time frame: 36 months
treatment tolerance
Time frame: 36 months
Death during induction
Time frame: 2 months
Death in complete remission
Time frame: 36 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma→
Versailles Hospital